Percutaneous transvenous mitral annuloplasty was feasible in 4 of 5 patients, reducing MR grade from 3.0 to 1.6, although device separation occurred in 3 of 4 implanted devices.
Is percutaneous transvenous implantation of an annuloplasty device safe and feasible in patients with chronic ischemic mitral regurgitation?
Percutaneous transvenous mitral annuloplasty via the coronary sinus is feasible and may reduce MR severity, but early device iterations experienced high rates of structural failure.
BACKGROUND: Mitral annuloplasty is the most common surgical procedure performed for ischemic mitral regurgitation (MR). Surgical mitral annuloplasty is limited by morbidity, mortality, and MR recurrence. We evaluated the safety and feasibility of a transvenous catheter-delivered implantable device to provide a percutaneous alternative to surgical mitral annuloplasty. METHODS AND RESULTS: Five patients with chronic ischemic MR underwent percutaneous transvenous implantation of an annuloplasty device in the coronary sinus. Implantation was successful in 4 patients. Baseline MR in the entire group was grade 3.0+/-0.7 and was reduced to grade 1.6+/-1.1 at the last postimplantation visit when the device was intact or the last postprocedural visit in the patient in whom the device was not successfully implanted. Separation of the bridge section of the device occurred in 3 of 4 implanted devices and was detected at 28 to 81 days after implantation. There were no postprocedural device-related complications. CONCLUSIONS: Percutaneous implantation of a device intended to remodel the mitral annulus is feasible. Initial experience suggests a possible favorable effect on MR. Percutaneous transvenous mitral annuloplasty warrants further evaluation as a less invasive alternative to surgical annuloplasty.
Webb et al. (Tue,) conducted a other in chronic ischemic mitral regurgitation (n=5). percutaneous transvenous mitral annuloplasty device was evaluated on safety and feasibility. Percutaneous transvenous mitral annuloplasty was feasible in 4 of 5 patients, reducing MR grade from 3.0 to 1.6, although device separation occurred in 3 of 4 implanted devices.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: